Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Natalizumab.

Joseph R Berger¹

¹Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic, Lexington, Kentucky 40536-0284, USA. jrbneuro@uky.edu

Drugs of Today (Barcelona, Spain : 1998)

|December 1, 2006

Summary

This summary is machine-generated.

Natalizumab, a biologic therapy for multiple sclerosis, effectively reduces relapses and lesions. However, it is associated with a rare risk of progressive multifocal leukoencephalopathy (PML).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Financial Value of an Academic Neurologist.

Annals of neurology·2026

Same author

Uremic pancreatitis following routine initiation of losartan in advanced chronic kidney disease: A case report.

SAGE open medical case reports·2026

Same author

The Effect of Ocrelizumab on Anti-JC Virus Antibody Index.

Brain and behavior·2026

Same author

Rapidly Progressive and Relapsing Myelitis With Human T Lymphotropic Virus Type 1: A Case Report and Review of the Literature.

Neurology(R) neuroimmunology & neuroinflammation·2026

Same author

GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Same author

Explaining the Insights Obtained from the BRANDO Database.

Arquivos de neuro-psiquiatria·2026

Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023

See all related articles

Area of Science:

Neuroimmunology
Pharmacology
Neurology

Background:

Biological agents targeting specific sites represent a new era in medical therapeutics.
Natalizumab, a humanized monoclonal antibody against alpha4 integrin, has shown promise in treating multiple sclerosis (MS).

Purpose of the Study:

To evaluate the efficacy and safety of natalizumab in managing multiple sclerosis.
To investigate the association between natalizumab treatment and the development of progressive multifocal leukoencephalopathy (PML).

Main Methods:

Intravenous administration of natalizumab at monthly intervals.
Monitoring of clinical trial participants for disease parameters, including relapse rates and MRI findings.
Surveillance for adverse events, specifically opportunistic infections like PML.

Related Experiment Videos

Main Results:

Natalizumab significantly decreased relapse rates and contrast-enhancing lesions in multiple sclerosis patients.
A rare but serious adverse event, progressive multifocal leukoencephalopathy (PML), was observed in three patients during clinical trials.
The estimated incidence of PML with natalizumab is approximately 1:1,000 after 18 months of therapy, with potential for higher rates with longer treatment durations.
No increased incidence of other opportunistic infections was noted, suggesting a specific link between natalizumab and PML.

Conclusions:

Natalizumab is a beneficial therapeutic agent for multiple sclerosis, improving key disease parameters.
The development of PML is a significant concern associated with natalizumab therapy, necessitating careful monitoring.
Further postmarketing surveillance is crucial to fully understand the risks and benefits of natalizumab, particularly its specific association with PML.